Another possibility is that visfatin and HDL-C are both modulated by shared metabolic or inflammatory pathways, such as those associated with insulin resistance, subclinical metabolic disturbances, or early atherosclerotic changes—even in the absence of clinically diagnosed metabolic syndrome. Here, NAMPT is linked to metabolic syndrome.